Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Victorion-RIDES in acute coronary syndrome
CTR20254585Phase 3Active
- Sponsor
- Novartis
- Start
- Feb 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of inclisiran in acute coronary syndrome (ACS), sponsored by Novartis. Started Feb 2026; status: active.
02
Drugs
inclisiran
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on CTR20254585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254585.